SCHEMBL752071

SCHEMBL752071

COCCNC(=O)Nc1cc[c]cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.50
THRB P10828 2/20 0.50
NAMPT P43490 2/20 0.50
NPC1 O15118 1/20 0.50
RAB9A P51151 1/20 0.50
ALDH1A1 P00352 6/20 0.49
POLB P06746 2/20 0.49
BDKRB1 P46663 1/20 0.46
LMNA P02545 2/20 0.46
MAPT P10636 3/20 0.45
KDM4E B2RXH2 2/20 0.45
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
MAPK1 P28482 1/20 0.45
EPHX2 P34913 1/20 0.45
APAF1 O14727 1/20 0.44
PABPC1 P11940 1/20 0.44
PTPN7 P35236 1/20 0.44
RECQL P46063 1/20 0.44
DUSP3 P51452 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22683516 0.91 ALDH1A1 (0.53) NAMPTALDH1A1POLBLMNAMAPT
SCHEMBL1415910 0.84 ALDH1A1 (0.44) SMN1; SMN2NAMPTALDH1A1LMNAMAPT
SCHEMBL10090175 0.83 LMNA (0.63) SMN1; SMN2NPC1RAB9AALDH1A1BDKRB1
SCHEMBL23457297 0.82 NPC1 (0.58) SMN1; SMN2THRBNAMPTNPC1RAB9A
SCHEMBL20590090 0.81 CNR1 (0.59) SMN1; SMN2THRBNAMPTNPC1RAB9A
SCHEMBL1416042 0.81 ATG4B (0.44) SMN1; SMN2NPC1RAB9AALDH1A1LMNA
SCHEMBL23406292 0.81 SMN1; SMN2 (0.54) SMN1; SMN2THRBNAMPTNPC1RAB9A
SCHEMBL1416499 0.80 ATG4B (0.43) SMN1; SMN2NPC1RAB9AALDH1A1LMNA
SCHEMBL1686953 0.80 RAB9A (0.40) SMN1; SMN2NPC1RAB9AALDH1A1LMNA
SCHEMBL1416157 0.80 KDM4E (0.49) SMN1; SMN2NAMPTNPC1RAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2430013-B1 HETEROARYL COMPOUNDS AS PIKK INHIBITORS AMGEN INC (US) 2014-10-15 EP claimed
US-20120190666-A1 Heteroaryl Compounds as PIKK Inhibitors AMGEN INC. (US) 2012-07-26 US claimed
EP-2430013-A1 HETEROARYL COMPOUNDS AS PIKK INHIBITORS Amgen, Inc (US) 2012-03-21 EP claimed
WO-2010132598-A1 HETEROARYL COMPOUNDS AS PIKK INHIBITORS AMGEN INC. (US) 2010-11-18 WO claimed
EP-2430013-B1 HETEROARYL COMPOUNDS AS PIKK INHIBITORS AMGEN INC (US) 2014-10-15 EP disclosed
US-20120190666-A1 Heteroaryl Compounds as PIKK Inhibitors AMGEN INC. (US) 2012-07-26 US disclosed
EP-2430013-A1 HETEROARYL COMPOUNDS AS PIKK INHIBITORS Amgen, Inc (US) 2012-03-21 EP disclosed
EP-2165830-B1 Lithographic printing plate precursor and printing method using the same FUJIFILM CORP (JP) 2011-03-16 EP disclosed
WO-2010132598-A1 HETEROARYL COMPOUNDS AS PIKK INHIBITORS AMGEN INC. (US) 2010-11-18 WO disclosed
US-20100071574-A1 LITHOGRAPHIC PRINTING PLATE PRECURSOR AND PRINTING METHOD USING THE SAME FUJIFILM CORPORATION (JP) 2010-03-25 US disclosed
EP-2165830-A1 Lithographic printing plate precursor and printing method using the same Fujifilm Corporation (JP) 2010-03-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120190666-A1 Heteroaryl Compounds as PIKK Inhibitors PIK3CA, PIKFYVE, PIK3CD SMN1; SMN2 3999/4885THRB 2396/4885NAMPT 1431/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.